Synergy of Host Defense Mechanisms in the Lung

肺部宿主防御机制的协同作用

基本信息

  • 批准号:
    8010956
  • 负责人:
  • 金额:
    $ 37.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1997
  • 资助国家:
    美国
  • 起止时间:
    1997-09-30 至 2012-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Host defense against the fungal pathogen Cryptococcus neoformans depends on both innate and acquired humoral and cellular immune mechanisms. Cryptococcal infection is acquired by inhalation. Therefore, the lung is the site of the initial encounter between host and microbe and the outcome of infection is decided by the local immune response. In the lung, the major host defense cell type is the alveolar macrophage. Recent studies have established that the alveolar macrophage plays a critical role in the outcome of cryptococcal infection. C. neoformans is a facultative intracellular pathogen that can replicate inside macrophages. Successful containment of cryptococcal infection involves the formation of granulomas where yeast cells can reside for long periods of time. Hence, the interaction between macrophages and C. neoformans is probably the most important determinant of the outcome of C. neoformans infection in that it governs both host defense and C. neoformans virulence and pathogenicity. In the past funding period the Casadevall laboratory made two discoveries related to C. neoformans-macrophage interactions. First, it was observed that phagocytosis triggers macrophage replication, a phenomenon that either benefits or harms the host depending on whether what ensues is one infected cell or two infected cells, respectively. Second, C. neoformans was shown to exit from infected macrophages through a mechanism that involves homotypic phagosome fusion and phagosome extrusion with survival of the host cell. This application proposes to dissect the outcome of C. neoformans phagocytosis with regards to fungal and host cell survival and damage, cell cycle progression and phagosome extrusion. Three specific aims are proposed: 1) To determine the outcome of C. neoformans phagocytosis by FcR and/or complement receptor; 2) To identify the mechanism of action and outcome of C. neoformans-induced cell cycle progression in macrophages; 3) To identify the mechanism of action and outcome of macro-phagosome exocytosis in macrophages. Completion of these studies is expected to shed new light on the two fundamental cellular processes of cell replication and phagocytosis and to provide new insights on the mechanisms of C. neoformans intracellular pathogenesis. Relevance. This application seeks funds to explore how the pathogenic fungus C. neoformans interacts with the most important host defense cell in the lungs. This information is important for understanding how the fungus establishes itself in the lungs and causes disease. Furthermore, these studies will provide information that could be used to design vaccines and new therapies based on immunological reagents such as Abs.Project Narrative: This application seeks funds to explore how the pathogenic fungus interacts with the most important host defense cell in the lungs. This information is important for understanding how the fungus establishes itself in the lungs and causes disease. Furthermore, these studies will provide information that could be used to design vaccines and new therapies based on immunological reagents such as antibodies.
描述(由申请方提供):宿主对真菌病原体新型隐球菌的防御依赖于先天性和获得性体液和细胞免疫机制。隐球菌感染通过吸入获得。因此,肺部是宿主与微生物最初接触的部位,感染的结果由局部免疫反应决定。在肺中,主要的宿主防御细胞类型是肺泡巨噬细胞。最近的研究已经确定肺泡巨噬细胞在隐球菌感染的结果中起着关键作用。C.新生儿是一种兼性细胞内病原体,可在巨噬细胞内复制。隐球菌感染的成功遏制涉及肉芽肿的形成,其中酵母细胞可以长时间驻留。因此,巨噬细胞与C. neoformans可能是C. neoformans感染,因为它控制宿主防御和C. neoforms毒力和致病性。在过去的资助期间,Casadevall实验室有两项与C。新生儿-巨噬细胞相互作用。首先,观察到吞噬作用触发巨噬细胞复制,这是一种对宿主有益或有害的现象,这取决于所捕获的是一个感染的细胞还是两个感染的细胞。第二,C.新形虫通过一种机制从感染的巨噬细胞中排出,该机制涉及同型吞噬体融合和吞噬体挤出,宿主细胞存活。本申请提出剖析C.关于真菌和宿主细胞存活和损伤、细胞周期进展和吞噬体挤出,新形线虫的吞噬作用。提出了三个具体目标:1)确定C的结果。通过FcR和/或补体受体的吞噬作用; 2)确定C. 3)确定巨噬细胞中巨噬体胞吐作用的作用机制和结果。这些研究的完成有望为细胞复制和吞噬这两个基本的细胞过程提供新的线索,并为C。细胞内发病机制。本案无关本申请旨在寻求资金,以探索致病真菌C。新生儿与肺中最重要的宿主防御细胞相互作用。这些信息对于了解真菌如何在肺部建立并导致疾病非常重要。此外,这些研究将提供信息,可用于设计疫苗和新的疗法的基础上免疫试剂,如抗体。项目叙述:本申请寻求资金,以探索致病真菌如何与肺部最重要的宿主防御细胞相互作用。这些信息对于了解真菌如何在肺部建立并导致疾病非常重要。此外,这些研究将提供可用于设计疫苗和基于免疫试剂(如抗体)的新疗法的信息。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Arturo Casadevall其他文献

Arturo Casadevall的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Arturo Casadevall', 18)}}的其他基金

The biology of Cryptococcus neoformans melanization
新型隐球菌黑化的生物学
  • 批准号:
    10660435
  • 财政年份:
    2023
  • 资助金额:
    $ 37.35万
  • 项目类别:
Exploiting antibody catalysis for treating Cryptococcosis
利用抗体催化治疗隐球菌病
  • 批准号:
    10326944
  • 财政年份:
    2021
  • 资助金额:
    $ 37.35万
  • 项目类别:
Exploiting antibody catalysis for treating Cryptococcosis
利用抗体催化治疗隐球菌病
  • 批准号:
    10410573
  • 财政年份:
    2021
  • 资助金额:
    $ 37.35万
  • 项目类别:
Exploiting antibody catalysis for treating Cryptococcosis
利用抗体催化治疗隐球菌病
  • 批准号:
    10609085
  • 财政年份:
    2021
  • 资助金额:
    $ 37.35万
  • 项目类别:
Conjugate vaccines for prevention and treatment of cryptococcosis - COVID-19 Revision Supplement
用于预防和治疗隐球菌病的结合疫苗 - COVID-19 修订补充资料
  • 批准号:
    10265635
  • 财政年份:
    2020
  • 资助金额:
    $ 37.35万
  • 项目类别:
Conjugate vaccines for prevention and treatment of cryptococcosis
用于预防和治疗隐球菌病的结合疫苗
  • 批准号:
    10339408
  • 财政年份:
    2020
  • 资助金额:
    $ 37.35万
  • 项目类别:
Conjugate vaccines for prevention and treatment of cryptococcosis
用于预防和治疗隐球菌病的结合疫苗
  • 批准号:
    10582699
  • 财政年份:
    2020
  • 资助金额:
    $ 37.35万
  • 项目类别:
Conjugate vaccines for prevention and treatment of cryptococcosis
用于预防和治疗隐球菌病的结合疫苗
  • 批准号:
    10117191
  • 财政年份:
    2020
  • 资助金额:
    $ 37.35万
  • 项目类别:
Biological and Clinical Impact of Cryptococcal Extralcellular Vesicles
隐球菌细胞外囊泡的生物学和临床影响
  • 批准号:
    8958486
  • 财政年份:
    2014
  • 资助金额:
    $ 37.35万
  • 项目类别:
Development of new passive immunization strategies for anthrax
开发新的炭疽被动免疫策略
  • 批准号:
    8230240
  • 财政年份:
    2011
  • 资助金额:
    $ 37.35万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 37.35万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 37.35万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 37.35万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.35万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 37.35万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 37.35万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 37.35万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 37.35万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 37.35万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 37.35万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了